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Background: Endovascular aneurysm repair (EVAR) is commonly used as a minimally invasive technique for repairing
infrarenal aortic aneurysms. There have been recent concerns that a subset of high-risk patients experience unfavorable
outcomes with this intervention. To determine whether such a high-risk cohort exists and to identify the characteristics
of these patients, we analyzed the outcomes of Medicare patients treated with EVAR from 2000-2006.
Methods: We identified 66,943 patients who underwent EVAR from Inpatient Medicare database. The overall 30-day
mortality was 1.6%. A risk model for perioperative mortality was developed by randomly selecting 44,630 patients; the
other one third of the dataset was used to validate the model. The model was deemed reliable (Hosmer-Lemeshow
statistics were P .25 for the development, P .24 for the validation model) and accurate (c 0.735 and c 0.731 for
the development and the validation model, respectively).
Results: In our scoring system, where scores ranged between 1 and 7, the following were identified as significant baseline
factors that predict mortality: renal failure with dialysis (score  7); renal failure without dialysis (score  3); clinically
significant lower extremity ischemia (score  5); patient age >85 years (score  3), 75-84 years (score  2), 70-74 years
(score  1); heart failure (score  3); chronic liver disease (score  3); female gender (score  2); neurological disorders
(score 2); chronic pulmonary disease (score 2); surgeon experience in EVAR<3 procedures (score 1); and hospital
annual volume in EVAR <7 procedures (score  1). The majority of Medicare patients who were treated (96.6%, n 
64,651) had a score of 9 or less, which correlated with a mortality <5%. Only 3.4% of patients had a mortality >5% and
0.8% of patients (n  509) had a score of 13 or higher, which correlated with a mortality >10%.
Conclusion: We conclude that there is a high-risk cohort of patients that should not be treated with EVAR because of
prohibitively highmortality; however, this cohort is small. Our scoring system, which is based on patient and institutional
factors, provides criteria that can be easily used by clinicians to quantify perioperative risk for EVAR candidates. ( J Vasc
Surg 2009;50:1271-9.)With a greater awareness through the liberal use of
cross-sectional imaging and enhanced screening efforts,
abdominal aortic aneurysms (AAA) are being identified
with increasing frequency.1,2 With multiple comorbidities
that are associated with an increased risk of intervention,
this population presents a unique challenge to vascular
interventionalists. Endovascular repair of AAA (EVAR) was
first introduced in 1991 by Parodi et al.3 Fifteen years later,
it appears that EVAR will soon become the predominant
method of AAA repair.4 Because it is minimally invasive,
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doi:10.1016/j.jvs.2009.06.061EVAR potentially holds great advantage for high-risk pa-
tients with multiple comorbidities. The procedure does not
require general anesthesia or intensive care unit (ICU)
admission postoperatively. Additionally, EVAR requires
only femoral artery exposure, eliminating the need for a
laparotomy and its complications. There is decreased blood
loss compared with open repair, and the major periopera-
tive intravenous fluid shifts observed with open repair are
avoided. It has been previously demonstrated that the
perioperative morbidity and mortality associated with en-
dovascular repair approaches one fourth that of traditional
open surgery.4
These advantages suggest that a broad spectrum of
AAA patients should be appropriate candidates for the
endovascular approach. However, the concept that EVAR
is applicable to all patients regardless of the severity of their
comorbidities has recently been challenged. In the EVAR 2
trial,5 Greenlaugh and coauthors identified a cohort of
patients “unfit for open repair” and randomized these
patients to EVAR versus medical treatment. These investi-
gators found that there was no significant difference in
all-cause mortality between medical treatment and EVAR,
with EVAR patients having a perioperative mortality of 9%.
These authors concluded that for high-risk AAA patients,
no surgical intervention is warranted. Despite valuable in-
sights from EVAR 2, there are unanswered questions: how
large is the subset of patients who are high risk for EVAR
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tify them?
Several studies have reported risk stratification para-
digms for open AAA repair.6-10 Subgroups of patients, who
are at high or even prohibitively high risk for conventional
AAA repair, have been identified. Variables that have been
commonly defined as pre-operative risk factors for mortal-
ity include: increased age, congestive heart failure (CHF),
myocardial ischemia, and renal and pulmonary dysfunc-
tion.6,7,9,11 By comparison, such risk factors have not been
identified for patients undergoing EVAR. Specification of
these risk factors is essential to delineate those patients at
prohibitive risk for EVAR who would benefit from medical
therapy alone. Thus, to better understand the mortality
associated with EVAR and, more importantly, to define
patients at excessively high risk for this “minimally invasive”
procedure, we analyzed the outcomes of Medicare patients
treated with EVAR between 2000 and 2006.
MATERIALS AND METHODS
Data sources and study population. We used the
Medicare Inpatient Standard Analytical file (Medicare part
A) to identify hospitalized patients who underwent EVAR
between 2000 and 2006. These files contain hospital-
discharge abstracts on 100% of Medicare-reimbursed hos-
pitalizations, except for those beneficiaries enrolled in
Medicare HMOs (approximately 10% of patients). The
data were supplemented with the Medicare Denominator
file, which contains demographic, geographic, and vital
status data. The data were obtained from the Centers for
Medicare and Medicaid Services (CMS).
Patients who underwent AAA repair were identified
through a combination of the International Classification
of Diseases, Clinical Modification (ICD-9-CM) diagnosis
code, 441.4 (aortic abdominal aneurysm without mention
of rupture) in the primary or any secondary position, plus
the primary or any secondary ICD-9-CM procedure code,
39.71 (endovascular implantation of graft in abdominal
aorta). If a patient had multiple AAA repairs, the first AAA
procedure was included in the analysis. Only patients with
elective admissions were included in this study. To ensure
that all comorbidities identified at prior hospitalizations
were not missed, we used a longer time period (1995-
2006) to define the comorbidities of patients who were
ultimately treated with EVAR.
It is often difficult to differentiate between pre-existing
comorbidities and postoperative complications (eg, stroke)
in large datasets. To address this weakness, we included a
diagnosis as a comorbidity if 1) it was present on a previous
hospital admission or 2) if it appeared during the index
hospitalization and was coded as a chronic or “acute on
chronic” disorder. The following comorbidities were as-
sessed (primary and all secondary diagnoses): cardiac dis-
ease (coronary artery disease, congestive heart failure
[CHF], valvular heart disease, cardiac arrhythmias), diabe-
tes, chronic pulmonary disease, peripheral arterial disease
(clinically significant lower extremity ischemia, vascular in-
sufficiency of the intestine, and renal atherosclerosis), renaldisease, neurological disorders (cerebrovascular, paralysis,
and other neurological diseases), cancer, rheumatoid ar-
thritis, and liver disease. The list of ICD-9 diagnosis codes
for comorbidities is provided in the Appendix (online
only). The annual hospital volume (number of EVAR/
year) and cumulative physician experience with EVAR at
the time of the procedure were used to develop a rela-
tionship between EVAR volume/experience and out-
come. All endovascular repairs (elective and ruptured)
were included in calculations of hospital volume and
surgeon experience.
Statistical analysis. To construct a risk model for
perioperative mortality after EVAR, all patients were ran-
domly allocated to a dataset for model development (the
training set; n  44,630, 2/3 of cohort) and a dataset for
model validation (the test set; n  22,313, 1/3 of the
cohort). In deriving the model, we first analyzed the uni-
variate associations between the independent variables (pa-
tient demographics, baseline comorbidities, hospital vol-
ume, and surgeon EVAR experience) and 30-daymortality.
Continuous variables (age, hospital volume, and surgeon
experience) were transformed into categorical variables.
Hospitals annual volume and surgeon experience were
categorized into 10 groups (deciles) with approximately
equal distribution of patients between groups. Patients less
than 65 years of age were excluded from the analysis to
avoid some confounding issues due to their disability as a
criterion forMedicare eligibility. Five-year increments were
used for age groupings. A Chi-square test was used to assess
the association between potential risk factors andmortality.
Variables with a level of significance (P value)  .25 were
included in a logistic regression analysis. This multivariable
regression model examines dichotomous outcomes (dead/
alive), and their associated risk factors. Only variables with
P value  .05 were included in the final model. The
interpretation of a risk factor included in the final model is
that it is independently associated with the event, control-
ling for other significant covariates, and all risk factors
jointly predict the event. Interactions between significant
predictors and age, gender, and race/ethnicity were also
tested. The diagnostic properties of the training model
were then tested using the validation dataset. The area
under the receiver operator curve (c statistic) was calculated
as a measure of discrimination or predictive ability. A value
of 1 indicates perfect discrimination. Calibration of the
model (statistical precision) was assessed by the Hosmer-
Lemeshow goodness-of-fit statistic. This statistic compares
observed number of patients with expected, derived by
logistic model. A P value for goodness of fit greater than
0.05 indicates that there is no statistical difference between
observed and expected numbers and that the model has a
high predictive ability. Risk factors were derived from the
training model and verified on validation dataset.
The regression coefficients of the risk factors were used
to develop a scoring system to predict 30-day mortality
after EVAR. Regression coefficients were multiplied by a
scaling factor and then rounded to the nearest integer.12The total risk score of a patient was the sum of the scores for
1.24
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model was constructed to evaluate the relationship between
total risk score and mortality. The model was created using
training dataset and was validated on test dataset. The
30-day mortality associated with total risk score was the
average risk among all patients having the same total score.
The accuracy of our scoring system was tested by compar-
ing the predicted mortality associated with each risk score
with the observed mortality on the validation dataset. All
statistical analyses were performed using the SAS system
software version 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
Risk factors: univariate analysis. We identified
66,943 patients age 65 or older who underwent EVAR
between 2000 and 2006. Since Medicare dataset provides
Table I. Patient demographics and 30-day mortality by de
Variable No. of patients %
Age, years
65-69 12,046
70-74 16,994
75-79 18,624
80-84 13,311
85 5,968
Male 55,485
Female 11,458
Whites 63,492
Blacks 1,847
Hispanics 354
Native Americans 118
Other races 830
Table II. Comorbidities and their association with 30-day
Comorbidity
No. of
patients % o
Renal failure w/dialysis 718
Renal failure w/o dialysis 2,554
PAD 4,855
LE ischemia 1,414
Vascular intestine 141
Renal atherosclerosis 3,409
Heart failure 9,644 1
Neurological disorders 7,494 1
Cerebrovascular and/or
paralysis
5,282
Other neurological 2,596
Liver disease 728
Cardiac arrhythmia 16,840 2
Rheumatoid arthritis 1,311
Valvular disease 6,364
Chronic pulmonary 24,854 3
Atherosclerosis 5,378
Cancer 5,135
Diabetes 11,013 1
Coronary disease 36,664 5
LE, Lower extremity; PAD, Peripheral arterial disease.date of surgery, we were able to identify conversion cases.We excluded 48 patients who had an open AAA repair prior
to an EVAR procedure during the same hospitalization.
However, we retained all conversions from EVAR to open
repair in the dataset. In terms of demographics, 8.9% of the
study population was 85 years of age or older, 82.9% were
males, and 94.8% were Caucasians (Table I). The overall
30-day mortality was 1.6%. The 30-day mortality after
EVAR among females was higher than among males (2.5%
vs. 1.4%; P .0001). Perioperative mortality also increased
with patient age; this became statistically significant for
patients 70 years of age or older (Table I).
A number of baseline comorbidities were associated
with 30-day mortality as shown in Table II. Common risk
factors included chronic pulmonary diseases (37.1% of co-
hort, mortality 2.0%, P  .0001), cardiac arrhythmia
raphic groups (n  66,943 patients)
ort Mortality (%) P value
0.9 (reference group)
1.2 0.04
1.6 0.0001
2.0 0.0001
3.2 0.0001
1.4 (reference group)
2.5 0.0001
1.6 (reference group)
1.9 0.29
2.0 0.55
1.7 0.92
0.7 0.05
rtality (N  66,943 patients)
rt Mortality (%) P value Odds ratio
11.8 .0001 9.01 [7.12-11.39]
3.8 .0001 2.64 [2.13-3.26]
3.1 .0001 2.17 [1.82-2.58]
6.2 .0001 4.42 [3.52-5.53]
2.8 0.23 1.82 [0.67-4.93]
1.9 0.09 1.24 [0.97-1.60]
3.5 .0001 2.88 [2.53-3.28]
2.4 .0001 1.63 [1.39-1.92]
2.1 0.0016 1.38 [1.13-1.68]
3.3 .0001 2.23 [1.79-2.80]
3.2 0.0006 2.05 [1.35-3.13]
2.3 .0001 1.78 [1.57-2.01]
2.3 0.04 1.47 [1.02-2.12]
2.2 .0001 1.44 [1.20-1.72]
2.0 .0001 1.49 [1.32-1.68]
1.7 0.49 1.08 [0.87-1.34]
1.7 0.57 1.07 [0.85-1.33]
1.6 0.80 0.98 [0.83-1.15]
1.5 0.03 0.88 [0.78-0.99]mog
of coh
17.99
25.39
27.82
19.88
8.92
82.88
17.12
94.84
2.76
0.53
0.17mo
f coho
1.07
3.82
7.25
2.11
0.21
5.09
4.41
1.19
7.89
3.88
1.09
5.16
1.96
9.51
7.13
8.03
7.67
6.45
4.77(25.2%, mortality 2.3%, P  .0001), and heart failure
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failure with dialysis represented only 1.1% of the cohort;
however, their risk of dying after EVAR was highest
(11.8%, P  .0001). Another less common risk factor
strongly associated with mortality, was clinically significant
lower extremity ischemia (2.1% of cohort, mortality 6.2%,
P  .0001).
Finally, we evaluated the relationship between hospital
annual volume and surgeon cumulative experience with
EVAR and perioperative mortality (Table III). Mortality
declined from 2.3% to 1.4%, with growing hospital annual
volume from less than seven procedures versus volume
greater than 73 EVARs (Table III). Thirty-day mortality,
when EVAR was performed by surgeons with total experi-
ence of  2 procedures, was 2.4%, whereas the mortality
was in the range of 1.3% to 1.6% for surgeons with a
cumulative EVAR experience  3 procedures.
Multivariable model. In a multivariable regression
model, the following baseline comorbidities predicted 30-
day mortality after EVAR: renal failure with dialysis (odds
ratio [OR] 7.06, P .0001) and without dialysis (OR
1.91, P  .0001), clinically significant lower extremity
ischemia (OR  3.55, P  .0001), liver disease (OR 
2.52, P  .0001), CHF (OR  2.23, P  .0001), neuro-
Table III. Annual hospital volume and cumulative
surgeon experience over the study period and their
association with 30-day mortality (n  66,943 patients)
Variable
No. of
patients
% of
cohort
Mortality
(%) P value
Hospital EVAR
Volume
(Annual,
deciles)
1-6 7,924 11.84 2.3 .0001
7-10 7,011 10.47 1.6 .33
11-14 6,649 9.93 1.8 .06
15-18 5,940 8.87 1.5 .85
19-23 6,571 9.82 1.4 .91
24-30 6,790 10.14 1.6 .39
31-37 6,126 9.15 1.4 .86
38-49 6,789 10.14 1.2 .34
50-73 6,469 9.66 1.5 .83
74 6,674 9.97 1.4 reference
Surgeon’s EVAR
experience
(cumulative,
deciles)
1-2 7,895 11.79 2.4 .0001
3-5 7,539 11.26 1.6 .16
6-8 5,844 8.73 1.8 .02
9-12 6,168 9.21 1.5 .36
13-18 6,957 10.39 1.5 .37
19-25 6,104 9.11 1.5 .36
26-36 6,597 9.85 1.5 .26
37-54 6,728 10.05 1.4 .63
55-93 6,504 9.72 1.4 .48
94 6,607 9.87 1.3 reference
EVAR, Endovascular aneurysm repair.logical disorders (OR  1.59, P  .0001), and chronicpulmonary diseases (OR  1.57, P  .0001) (Table IV).
The risk of death after EVAR was 68% higher for females
versus males (OR  1.68, P  .0001) and increases with
patient age: OR  1.40 for patients 75-79 years of age to
OR  3.10 for patients 85 years of age, controlling for
comorbidities, gender, hospital volume, and surgeons ex-
perience. Hospital volume ( 7 EVARs per year) remained
in the model as a predictor of death after surgery, as did
surgeon experience of 3 EVAR procedures at the time of
the index operation.
Using the receiver operating curve characteristics, we
found that the c-indices were 0.735 for the training set and
Table IV. Statistically significant predictors of 30-day
mortality after EVAR AAA (based on the results of
multivariable logistic regression model, concordance
index  0.735, Hosmer-Lemeshow goodness of fit test
P  .25)
Risk factor Parameter
Odds ratio and
95% CL P value
Renal failure w/
dialysis 1.95 7.06 [5.23-9.53] .0001
LE ischemia 1.27 3.55 [2.65-4.75] .0001
Age  85 years 1.13 3.10 [1.57-2.37] .0001
Liver disease 0.93 2.52 [1.54-4.12] .0002
CHF 0.80 2.23 [1.89-2.64] .0001
Renal failure w/o
dialysis 0.65 1.91 [1.45-2.51] .0001
Age 80-84 years 0.65 1.92 [1.56-2.36] .0001
Female 0.52 1.68 [1.42-1.99] .0001
Neurological 0.45 1.59 [1.29-1.94] .0001
Chronic pulmonary 0.45 1.57 [1.35-1.83] .0001
Hospital annual
vol 7 0.37 1.45 [1.18-1.80] .0005
Age 75-79 years 0.34 1.40 [1.14-1.71] 0.001
Surgeon EVAR
vol 3 0.26 1.30 [1.04-1.62] .002
CHF, Congestive heart failure; EVAR, endovascular aneurysm repair; LE,
lower extremity.
Table V. Risk scores for 30-day mortality for EVAR
patients
Risk factor Score
Renal failure w/dialysis 7
LE ischemia 5
Age  85 years 4
Liver disease 3
CHF 3
Renal failure w/o dialysis 3
Age 80-84 years 2
Female 2
Neurological 2
Chronic pulmonary 1
Surgeon EVAR experience 3 1
Hospital annual volume 7 1
Age 75-79 years 1
CHF, Congestive heart failure; EVAR, endovascular aneurysm repair; LE,
lower extremity.0.731 for the test set, indicating the robust predictive
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of fit statistics (comparison of observed and expected
deaths) were 0.25 and 0.24 for training and test datasets
respectively, indicating good statistical precision of the
models.
Risk score. Table V depicts risk scores for every statis-
tically significant risk factor. Risk scores ranged from a
minimum of one point for chronic pulmonary disorders to
a maximum of seven points for renal failure with dialysis.
The total risk score was obtained by summing individual
risk points. The regression model that evaluated the rela-
tionship between total risk score and 30-day mortality was
deemed reliable (Hosmer-Lemeshow statistics was P .06
for the development, P .83 for the validation model) and
accurate (c  0.73 and c  0.70 for the development and
the validation model, respectively).
The relationship between predicted 30-day mortality
after EVAR and patients’ total risk score is presented in
Table VI. The estimated mortality ranged from 0.5% to
38.4% for risk scores that ranged from 0 to 20. We then
evaluated the agreement between predicted and observed
mortality by risk score (Fig 1). The correlation between
observed mortality (test dataset) and expected mortality
(training dataset) using this model was very strong; r2 
0.83 (P  .0001).
The distribution of patients by risk score is shown in
Fig 2: 96.6% (n 64,651) of patients had a score of nine or
less, which correlated with a mortality of less than 5%; 3.4%
of patients (n  2,292) had a score 9 and a mortality
greater than 5%. Only 0.8% of patients (n  509) had a
score of 13 or higher, which correlated with a mortality of
Table VI. Predicted mortality based on scoring system
Total risk score
Predicted 30-day
mortality (%) No. of patients
0 0.5 9907
1 0.7 7516
2 0.9 12005
3 1.1 9281
4 1.4 7656
5 1.7 6532
6 2.2 4715
7 2.8 3403
8 3.5 2274
9 4.4 1462
10 5.5 892
11 6.8 543
12 8.5 348
13 10.6 213
14 13.0 99
15 15.6 87
16 19.4 46
17 23.4 35
18 27.9 7
19 32.9 7
20 38.4 8greater than 10%.DISCUSSION
Numerous studies have compared the outcomes of
open repair with EVAR, and the benefits of EVAR in terms
of more intermediate outcomes have been well documen-
ted.6,13-20 However, concerns have arisen as to whether
EVAR is a sufficiently low-risk procedure that it can be used
safely in all patients with AAA 5.5 cm. Greenlaugh and
colleagues addressed this question with the EVAR trial 2.
They identified a perioperative mortality of 9% in a popu-
lation of patients with large aneurysms “unfit” for open
surgery repaired with endovascular techniques.5 These au-
thors were the first to recognize and report the limitations
Fig 1. Relationship between observed and predicted mortality by
total score. Predicted mortality was estimated based on logistic
regression model of two thirds of the cohort (development sam-
ple). Observed mortality was depicted from the remaining one
third of the cohort (test sample). Coefficient of correlation be-
tween observed and predicted mortality r2  0.8294. Number of
observations in the test sample by score: 1 – 3229, 2 – 2497, 3 –
4051, 4 – 2573, 5 – 2135, 6 – 1555, 7 – 1104, 8 – 800, 9 – 475,
10 – 312, 11 – 186, 12 – 130, 13 – 69, 14 – 24, 15 – 31, 16 – 15,
17 – 11, 18 – 2, 19 – 0, 20 – 3.
Fig 2. Distribution of patients by risk scores.of EVAR and raise the notion that this technique should
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However, the definitions used for high risk in EVAR trial 2
remain somewhat elusive. Guidelines for determining pa-
tient enrollment in EVAR trial 2 have been published;21
however, “physician discretion” was also used in determin-
ing which patients were ultimately eligible for this trial. The
insights provided by EVAR 2 are important. There is most
certainly a population of patients with large aneurysms that
are better treated medically than with surgical intervention.
However, questions still remain about the risk factors that
predict mortality in patients undergoing EVAR and the size
of the population of patients that are truly high risk.
Sicard et al retrospectively analyzed data from five
multi-center EVAR clinical trials to further characterize
outcomes after EVAR.22 These authors reported a 30-day
mortality of 2.9% in a population of 565 patients that they
defined as high risk, based upon criteria derived from
EVAR trial 2 that included one or more of the following
comorbidities: severe valvular disease, significant arrhyth-
mia, uncontrolled CHF, dyspnea with stair climbing, poor
pulmonary function, hypoxemia, hypercarbnia, or a serum
creatinine  2.27mg/dL.21 The mortality observed by
Sicard et al was dramatically less than that found in EVAR 2
(2% versus 9%). Although there are several possible expla-
nations for the dramatic difference in findings of the two
studies, the most likely is that the “high risk” population
defined by Sicard is indeed different than the high-risk
cohort studied in EVAR trial 2. Patients recruited into
clinical trials are usually homogeneous and patients with
poor longevity or those at extremely high risk are often
excluded from pivotal investigations. There are also exclu-
sion criteria in clinical trials that eliminate patients with
unfavorable arterial anatomy. It has previously been dem-
onstrated that endovascular repair in patients with favorable
anatomy is less risky. Despite apparent differences in mor-
tality outcomes in these two studies, one can conclude from
both that there is indeed a cohort of patients who are high
risk for EVAR.
Our analysis further addresses this issue by providing
information about the factors that define patients at high
risk for EVAR. As well, we have provided insight into the
size of the cohort that has a prohibitively high mortality. Of
the almost 67,000 patients evaluated in this study, a risk of
perioperative mortality of 9% or greater (the EVAR2 out-
come) was found in only 1.3% of the treated population.
We have also identified preoperative characteristics that can
determine this small but high-risk cohort. We found that
renal failure, lower extremity vascular disease, liver disease,
neurological disorders, female gender, age, hospital vol-
ume, surgeon experience, heart failure, and chronic pulmo-
nary diseases all increased the potential of death within 30
days following EVAR.
Multiple similar analyses have been performed for pa-
tients undergoing open aneurysm repair.7-10 Although the
demographic factors and comorbidities that increase mor-
tality are similar for open and endovascular repair, their
relative importance appears to differ. For EVAR, we found
risk factors in descending order of importance to be: renalfailure with dialysis, lower extremity ischemia, age 85
years, liver disease, CHF, renal failure without dialysis,
female gender, a neurological disorder, chronic obstructive
pulmonary disease, and low hospital volume and surgeon
experience with EVAR. For open repair, renal failure leads
the list (similar to EVAR), but is followed by myocardial
disorders, such as ischemia and CHF, then pulmonary
disease, age, and female gender.10 One might predict that
major heart and/or lung disease is of less relevance as a risk
factor for endovascular aneurysm repair versus open repair
and this appears to be the case. Perhaps it is not surprising
that CHF or pulmonary disease are less important predic-
tors of death in EVAR since the surgical intervention (groin
cut-downs) is associated with a less profound physiologic
demand on the heart and lungs.23 In fact, the factors that
lead to mortality following EVAR may be related more to
complex arterial anatomy than to complex patient physiology.
Our multivariate analysis revealed that patients at high-
est risk are those with renal failure. Findings from the
EUROSTAR registry were similar.24 The increase in mor-
tality associated with renal disease is possibly due to the
high prevalence of multifocal atherosclerosis in these pa-
tients, including the heart and cerebrovascular circulation.
Also of great significance is the strong association between
renal failure and calcified and diseased iliac arteries.25,26
When performing an EVAR in a patient with renal failure,
the interventionalist may be faced with heavily calcified,
tortuous, and narrowed iliac arteries that are difficult to
navigate with an endovascular device. The consequence can
be arterial rupture, occlusion, and the need for a conduit or
a prolonged intervention. Thus, renal failure may be a
surrogate for complex arterial anatomy. Unfortunately, one
of the limitations of large datasets, such as Medicare, is the
absence of information about anatomy; therefore, we are
unable to verify this hypothesis.
A number of additional risk factors predicted perioper-
ative mortality. Patients with lower extremity vascular dis-
ease are at increased risk presumably for the same reason as
those with renal failure. Lower extremity vascular disease is
also a marker for generalized atherosclerosis, including
myocardial insufficiency. Patients with chronic liver disease
experience greater morbidity and mortality following most
elective surgeries.27 In two small prospective studies, the
influence of gender on outcome of EVAR was evaluated
and no differences were found between men and women
with respect to 30-day mortality.28,29 In both studies,
however, it was noted that women have a significantly
higher rate of aborted procedures, less deployment success,
and an increased risk of access-related complications. The
lack of an association between gender andmortality in these
smaller studies may be due to the small sample size, (n 
26)29 and (n  24).28 The increased mortality that we
observed in women may be largely related to anatomic
issues. Anatomical characteristics inherent to women in-
clude shorter infrarenal necks, smaller proximal neck diam-
eters, and smaller diameters of iliac (access) arteries.29
Neurological disorders, including a prior history of
cerebrovascular accident and transient ischemic attack,
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increase 30-day mortality by 59% in our multivariable re-
gression model. Cerebrovascular disease has been observed
to increase peri-procedural complications and mortality,
and has, therefore, been included in several preoperative
scoring systems, including the Revised Cardiac Risk In-
dex,30 Glasgow aneurysm score,31 and the Customized
Probability Model.32 Additionally, we found surgeons just
beginning their EVAR practice, as well as hospitals with
lower annual volumes of EVARs, to have significantly
higher perioperative mortality. We are not able to deter-
mine if surgeons at the early phase of their experience with
EVAR are in mentored situations such as a group practice
or an academic medical center. Possibly this might explain
the low number of procedures necessary to gain expertise.
Such volume-outcome relationships have long been recog-
nized for open aneurysm repair33 and it should be noted
that despite the same opportunity for mentoring with open
repair, the number of procedures necessary to achieve
proficiency is significantly higher than for endovascular
repair. We have composed a scoring system that can be used
to assist interventionalists and patients. Assessing the surgi-
cal risk of a patient with multiple comorbidities can be
remarkably difficult, yet it is these particular patients who
benefit most from an accurate preoperative evaluation, as
they are likely to have increased early and late mortality as a
consequence of their associated illness. Preoperative risk
stratification for noncardiac vascular surgery has been in-
vestigated by others and validated, using mathematical
models to derive scoring systems and predict mortal-
ity.10,30-32,35-37 Analysis of a large Medicare dataset pro-
vides sufficient statistical power to accurately identify spe-
cific individual criteria predictive of 30-day mortality for
EVAR. Our scoring system allows a comparison of the
impact of individual factors on mortality, and importantly,
a summation of their combined effects. It is our hope that
this scoring system can be used by the practicing interven-
tionalist to identify those who are indeed candidates for
EVAR. For example, a patient with CHF and chronic
pulmonary disease would be at relatively low risk for repair
(total score of four). Alternatively, a female patient with
renal failure would be of profoundly high risk (total score of
nine). We realize that scoring systems have their limita-
tions, and in the real world clinicians need to individualize
therapeutic decisions for patients. However, the scoring
system that we have devised does take into account the
majority of pertinent risk factors and could potentially be
used as a guide to assist clinicians in their evaluation of
patients with aneurysmal disease. Admittedly, our scoring
system does not directly assess the important effect that
vascular anatomy may have on outcome.
Other risk stratification systems have been employed to
predict outcome of endovascular aneurysm repair.34,35 Pa-
tients included in a randomized trial such as Dutch Ran-
domized Endovascular Aneurysm Management (DREAM)36
are selected and often more homogenous than those
treated in standard practice. For example, many of the very-
high-risk patients that are included in the Medicare database would not have passed screening criteria for a random-
ized trial. Moreover, in this analysis we have created a de
novo scoring system from the data available rather than
attempting to retrofit a scoring system previously designed
for open repair for EVAR. That said, this is one of several
proposed methodologies for risk-stratifying patients pro-
posed for EVAR, and only future studies on new cohorts of
patients will determine which of these systems has the
greatest validity.
There are a number of limitations of administrative
datasets that should be noted. First, knowledge of the
severity of comorbidities is often lacking. Second, diagnosis
codes are broad and vague and provide limited detail about
the specific patient disease state. By accepting only comor-
bidities that are coded as chronic or that have been present
on previous admissions, we may miss occasional comorbid-
ites that have appeared between hospitalizations or that are
not associated with a “chronic” code. By assuming this
approach, we have likely increased our accuracy but may
have also, to some extent, diminished our sensitivity. This is
a common approach that is used in the evaluation of
administrative data bases and overall the trade-off of accu-
racy for sensitivity is thought to be desirable. The third
limitation, and possibly themost important for this analysis,
is the lack of information regarding patient anatomy. We
are not able to understand which of these 66,943 patients
had diseased iliac arteries, nor do we know the size of the
aneurysms treated. Lastly, as with all administrative data-
sets, there is the potential for coding inaccuracies and
oversights. The effect of coding issues are likely diminished
by the “randomization” of non-systematic errors that re-
sults when massive numbers of observations are statistically
analyzed.37 These limitations aside, the distinct advantage
of administrative data bases such as Medicare, is the very
large sample size. Our report of almost 67,000 EVARs is
one of the largest ever published. This population-based
dataset is rich in information regarding diagnoses, proce-
dures, and demographics and is a true representation of
clinical practice in the United States.
We determine high-risk EVAR patients by using a
cohort of patients who have already undergone EVAR.
This approach is frequently used to support clinician deci-
sion making on patient eligibility for various surgical pro-
cedures, including open repair of AAA.7,9 However, it is
important to note that clinical judgments made before
patients receive EVAR may involved a different weighting
of factors and may also take into account additional param-
eters versus those considered in this study. Our study
stratifies operative risk only for patients already selected for
EVAR. In the absence of compelling level I evidence (a
randomized clinical trial of intervention versus no interven-
tion), a retrospective analysis of surgical outcomes has
proven to be a useful approach for operative risk stratification.
It should be noted that multiple studies have sup-
ported a considerably high incidence of death from
rupture in high-risk AAA cohorts that are treated conser-
vatively.21,38,39 Thus, a significant portion of the AAA
population will likely die from rupture if they are excluded
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subgroup of patients who are indeed high risk for endovas-
cular repair. However, we also show that this cohort of
patients is exceedingly small. In sum, we believe that EVAR
is safe and effective in the majority of the elderly popula-
tion, even those with multiple comorbidities. The propor-
tion of patients truly unfit for EVAR is small. Moreover, we
feel that the described scoring system can be a useful aid to
preoperatively identify patients unfit for even minimally
invasive treatment of their aneurysm.
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Predictive assessment of mortality and morbidity remains an
important component of preoperative evaluation of any surgical pro-
cedure. Most preoperative risk assessment models have been devel-
oped for open surgical procedures with variable predictability.1,2 The
introduction and widespread use of less invasive surgical proce-
dures, either by laparoscopic or endovascular techniques has
heightened the need for developing new risk models that could
predict postoperative mortality and morbidity.
Treatment of abdominal aortic aneurysm has undergone dra-
matic changes in the last two decades. Despite the many advances
in anesthetic management, preoperative risk factor modifications,
and postoperative care, the 30-daymortality has remained between
3% and 5% with higher mortality and morbidity in high-risk
patients.3 Despite the significant threefold reduction in mortality
in single centers, statewide databases and randomized trials, com-
pared with conventional open repair, no analysis of criteria has
been performed that can objectively identify those risk factors
that increase 30-day mortality in endovascular aneurysm repair
(EVAR). The EVAR 2 trial used a series of medical risk factors and
“pragmatic” approaches to deem a patient unsuitable for AAA
repair.4 Our group reported much lower 30-day mortality (2.9% vs
9%) for high-risk patients compared with EVAR 2 trial based on
medical comorbidities.5 Both reports were based on risk factors
commonly used to predict mortality in open repair not specific to
EVAR.
In this issue, Drs Egorova, Giacovelli, and collaborators de-
scribe an extensive analysis of the Inpatient Medicare database of
patients with elective abdominal aortic aneurysm (AAA) repair
from 2000 to 2006 and develop a risk model of preoperativethough some of the preoperative comorbidities that predict higher
30-day mortality are similar to those described for open repair,
some factors are different and other similar factors have a different
predictor effect on 30-day outcomes. This preoperative score, as a
predictor of 30-day mortality, provides for the first time, an objec-
tive indicator of the mortality risk specific for EVAR in high-risk
patients. Another important observation of this report is the iden-
tification of a very small number of EVAR candidates that are truly
very high-risk even for this less invasive procedure. This preopera-
tive predictive score will be of great utility to interventionalists who
frequently perform EVAR.
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Comorbidity
Index ho
Congestive heart failure 398.91, 402.01, 402.1
425.5, 425.7, 425.8
428.42, 428.9
Cardiac arrhythmia 426.0, 426.10, 426.11
V45.0, V53.3
Valvular disease 093.2, 394, 395, 396,
Coronary disease 412, 413, 414, 429.2
Diabetes 250
Hypertension 401, 402, 403, 404, 4
Pulmonary diseases 416, 417.9, 490, 491, 4
495.9, 496, 500, 501
Clinically significant lower extremity
vascular diseases
440.22, 440.23, 440.2
Renal atherosclerosis 440.1
Vascular intestine disease 557.1
Renal failure with dialysis V45.1, V56.0, V56.1,
Renal failure without dialysis 403.01, 403.11, 403.9
(w/o 585.6), 588.0
Other renal diseases 582, 583.0, 583.1, 58
Kidney transplant V420
Liver disease 070.22, 070.23, 070.3
572.3, 572.4, 572.8
Cerebrovascular diseases and paralysis 342, 344.1, 344.3, 34
Other neurological diseases 330, 331, 332, 333, 3
335.9, 336.0, 336.2
437.6, 437.7
Cancer 140, 141, 142, 143, 1
157, 158,159, 160,
181, 182, 183, 184
198, 199, 200, 201
Rheumatoid arthritis 446, 701.0, 710.0, 71
725, 728.5, 728.89
Pre-index
History of heart failure 398.91, 402.01, 402.1
425.5, 425.7, 425.8
Cardiac arrhythmia 426, 427.0, 427.1, 42
Valvular disease 093.2, 394, 395, 396,
Coronary disease 410, 412, 413, 414, 4
Pulmonary 415, 416, 417, 490, 4
506.2, 506.4, 506.9
Clinically significant lower extremity
vascular diseases
440.22, 440.23, 440.2
Renal atherosclerosis 440.1, 445.81
Vascular intestine disease 557.1, 557.9
Hypertension 401, 402, 403, 404, 4
Cerebrovascular diseases and paralysis 342, 344.1, 344.3, 34
437.8, 437.9, 438,
Other neurological diseases 330, 331, 332, 333, 3
335.1, 335.2, 335.8
348.3, 430, 431, 43
Diabetes 250
Dialysis V45.1, V56.0, V56.1,
Renal failure without dialysis 403.01, 403.11, 403.9
(w/o 585.6), 586, 5
Renal diseases 582, 583.0, 583.1, 58
Liver disease 070.22, 070.23, 070.3
572.2, 572.3, 572.4
Cancer 140, 141, 142, 143, 1
157, 158,159, 160,
181, 182, 183, 184
198, 199, 200, 201
Kidney transplant V42.0
Rheumatoid arthritis 446, 701.0, 710.0, 71
725, 728.5, 728.89morbidities
ICD9 code
spitalization
1, 402.91, 404.01, 404.03, 404.11, 404.91, 404.13, 404.93, 425.4,
, 425.9, 428.0, 428.1, 428.20, 428.22, 428.30, 428.32, 428.40,
, 426.12, 426.13, 426.7, 426.9, 427.0, 427.1, 427.2, 427.3, 427.9,
397, 424, V42.2, V43.3
05
92, 493, 494, 495.0, 495.1, 495.2, 495.3, 495.4, 495.5, 495.6, 495.8,
, 502, 503, 504, 505, 506.0, 506.2, 506.4, 506.9, 508.1, 508.8, 508.9
4, 440.3, 444.22, V43.4,
V56.2, V56.3, V56.8, 585.6, 39.95 (w/o 586)
1, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585
3.2, 583.4
2, 070.33, 070.44, 070.54, 070.9, 456.0, 456.1, 571, 572.1, 572.2,
, 573.0, 573.1, 573.8, 573.9
4.4, 344.5, 344.9, 437.0, 438
34.0, 334.1, 334.2, 334.4, 334.8, 335.0, 335.1, 335.2, 335.8,
, 343, 344.0, 348.1, 348.3, 344.2, 344.6, 345, 437.3, 437.4, 437.5,
44,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156,
161, 162, 163, 164, 165, 170, 171,172, 174, 175, 176, 179, 180,
, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197,
, 202, 203.0, 238.6
0.1, 710.2, 710.3, 710.4, 710.8, 710.9, 711.2, 719.3, 714, 720,
hospitalizations
1, 402.91, 404.01, 404.03, 404.11, 404.91, 404.13, 404.93, 425.4,
, 425.9, 428
7.2, 427.3, 427.4, 427.5, 785.0, 996.01, 996.04, V45.0, V53.3
397, 424, V42.2, V43.3
29.2
91, 492, 493, 494, 495, 496, 500, 501, 502, 503, 504, 505, 506.0,
, 508
4, 440.3, 444.22, 996.7, V43.4
05, 458.0, 458.1, 458.8, 458.9
4.4, 344.5, 344.9, 362.30, 362.31, 362.34, , 433, 434, 435, 436,
784.3
34.0, 334.1, 334.2, 334.3, 334.4, 334.8, 334.9, 336.0, 335.0,
, 335.9, 336.0, 336.2, 340, 343, 344.0, 344.2, 344.6, 345, 348.1,
2, 437.3, 437.4, 437.5, 437.6, 437.7, 780.3
V56.2, V56.3, V56.8, 585.6, 39.95
1, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585
88.0
3.2, 583.4, 583.6, 583.7
2, 070.33, 070.44, 070.54, 070.6, 070.9,456.0, 456.1, 456.2, 571,
, 572.8, 573
44,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156,
161, 162, 163, 164, 165, 170, 171,172, 174, 175, 176, 179, 180,
, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197,
, 202, 203.0, 238.6
0.1, 710.2, 710.3, 710.4, 710.8, 710.9, 711.2, 719.3, 714, 720,
